CAMBRIDGE, Mass., Jan. 12, 2024 – Arena BioWorks announces its inauguration as a leading-edge biomedical research institute. With its mission firmly rooted in deciphering the mechanisms of human diseases and propelling technological innovations, Arena BioWorks is poised to transform these insights into lifesaving therapeutics through its internal biotech companies.

 

Co-Founders and Visionaries

The foundation of Arena BioWorks is underpinned by a distinguished group of co-founders. Stuart Schreiber, a renowned scientist from Harvard University and co-founder of the Broad Institute, joins forces with Steve Pagliuca, former Co-Chair of Bain Capital, and Tom Cahill of Newpath Partners, a life science venture capital firm. This trio brings a blend of scientific acumen and visionary leadership to the institute.

 

Core Scientific Team

The scientific endeavors at Arena BioWorks are spearheaded by leaders in their respective fields. Stuart Schreiber and Keith Joung lead the team, with other eminent scientists set to join. Their expertise in chemical biology and CRISPR gene editing is central to the institute’s innovative research trajectory.

 

Founding Investors

The institute’s initial phase has been made viable through the substantial backing of Steve Pagliuca, Michael Dell, Michael Chambers, Jim Breyer, and Elisabeth DeLuca. Their support establishes a foundational model for self-sustainability at Arena BioWorks.

 

Arena’s Novel Approach

Distinct in its operation, Arena BioWorks departs from conventional research models by utilizing a private funding approach. This strategy facilitates a swifter transition from insight discovery to practical application, free from the usual constraints of grant and venture capital dependencies. Arena BioWorks’ research encompasses a broad spectrum of diseases, harnessing a suite of advanced technologies including chemoproteomics, gene editing, and artificial intelligence.

 

Leadership and Impact

Under the stewardship of Stuart Schreiber, Steve Pagliuca, and Tom Cahill, Arena BioWorks is guided by an amalgamation of expertise in biotechnology, venture capitalism, and scientific innovation. The institute aspires to be a perpetual center of excellence, reinvesting its profits back into ongoing research and development. This innovative model sets a new standard in the biomedical research field.

Source:
https://www.nytimes.com/2024/01/12/business/arena-bioworks-scientists-harvard-mit.html
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

How to make mRNA therapeutics safe from the start

The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...

read more

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE